Evidence map›Paper›PMID 33767621›Full record

ArticleFrontiers in pharmacology2021

A Potential Mechanism Underlying the Therapeutic Effects of Progesterone and Allopregnanolone on Ketamine-Induced Cognitive Deficits.

Ting Cao, MiMi Tang, Pei Jiang, BiKui Zhang, XiangXin Wu, Qian Chen, CuiRong Zeng, NaNa Li, ShuangYang Zhang, HuaLin Cai

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Neurosteroid enantiomers as potentially novel neurotherapeutics.Neuroscience and biobehavioral reviews · 2023
    Review
  6. Advantages and Limitations of Animal Schizophrenia Models.International journal of molecular sciences · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ting CaoDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
MiMi TangDepartment of Pharmacy, Xiangya Hospital of Central South University, Changsha, China.
Pei JiangInstitute of Clinical Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.
BiKui ZhangDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
XiangXin WuDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
Qian ChenDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
CuiRong ZengDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
NaNa LiDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
ShuangYang ZhangDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
HuaLin CaiDepartment of Pharmacy, Second Xiangya Hospital, Central South University, Changsha, China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNJining First People's Hospital · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketamine exposure can model cognitive deficits associated with schizophrenia. Progesterone (PROG) and its active metabolite allopregnanolone (ALLO) have neuroprotective effects and the pathway involving progesterone receptor membrane component 1 (PGRMC1), epidermal growth factor receptor (EGFR), glucagon-like peptide-1 receptor (GLP-1R), phosphatidylinositol 3 kinase (PI3K), and protein kinase B (Akt) appears to play a key role in their neuroprotection. The present study aimed to investigate the effects of PROG (8,16 mg kg

Indexed as

allopregnanolonecognitive deficitsketamineneuroprotectionPGRMC1 signalingprogesterone

Identifiers

PMID33767621
PMCPMC7985688
OpenAlexW3133936492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.